Chronic Obstructive Pulmonary Disease Treatment Market Size Report 2034: Insights Into Therapies, Research, and Market Potential

DelveInsight's "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology and the COPD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Chronic Obstructive Pulmonary Disease Market Share @ Chronic Obstructive Pulmonary Disease Market Outlook- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Report
• DelveInsight's analyst estimate that approximately 44.2 million Diagnosed Prevalent Cases of COPD were found in 2023 in the 7MM.
• The United States exhibited the highest diagnosed prevalent population of COPD, as compared to other 7MM countries. As per DelveInsight's estimations, the Total Diagnosed Prevalent Cases of COPD in the US was around 18.3 million in 2023 and is projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis and increasing awareness among the patient population.
• According to DelveInsight's estimates, the Total Diagnosed Prevalent Cases of COPD in EU4 and the UK were found to be ~18.6 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of COPD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.
• The estimates show the Total Diagnosed Prevalent Cases of COPD in Japan was found to be around 7.2 million in 2023, which is estimated to increase by 2034 at a significant CAGR.
• The Gender-specific Cases of COPD in the UK were ~1.7 million for females and ~2 million for males in 2023 and are expected to increase within the forecast period (2024-2034). The increased prevalence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.
• According to the analysis performed by DelveInsight's experts, the Age-specific Cases of COPD were categorized into 18-44 years, 45-54 years, 55-64 years, 65-74 years, and 75+ years. The higher number of cases (~4.8 million) was accounted for by the 55-64 year age group in 2023 in the US.
• The Diagnosed Prevalence of COPD Based on Severity of Airflow Limitation was categorized into GOLD (Global Initiative for Chronic Obstructive Lung Disease) 1-4. According to DelveInsight estimates, a higher number of patients were estimated in the GOLD 2 category, with approximately 1.9 million cases in 2023 in Germany.
• The GOLD guidelines combine FEV1 reduction, dyspnea, and exacerbation history to classify patients with COPD into Groups A-D. According to estimations by DelveInsight's analysts, the Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History were higher in the GOLD A category in the US with nearly 9.8 million cases in 2023.
• The leading Chronic Obstructive Pulmonary Disease Companies such as Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others.
• Promising Chronic Obstructive Pulmonary Disease Therapies such as Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.

Stay ahead in the Chronic Obstructive Pulmonary Disease Therapeutics Market with DelveInsight's Strategic Report @ Chronic Obstructive Pulmonary Disease Treatment Market- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation in the 7MM
• Total Prevalence of Chronic Obstructive Pulmonary Disease
• Prevalent Cases of Chronic Obstructive Pulmonary Disease by severity
• Gender-specific Prevalence of Chronic Obstructive Pulmonary Disease
• Diagnosed Cases of Episodic and Chronic Chronic Obstructive Pulmonary Disease

Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease Epidemiology trends @ Chronic Obstructive Pulmonary Disease Prevalence- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Marketed Drugs
• Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca
Approved in April 2019, Duaklir (aclidinium bromide/formoterol fumarate 400 μg/12 μg twice-daily) is a fixed-dose LAMA/LABA combination of two long-acting bronchodilators - aclidinium bromide is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta-agonist (LABA). Duaklir Pressair contains two bronchodilators: aclidinium, a long-acting muscarinic antagonist (also known as an anticholinergic), and formoterol, a long-acting beta-2-adrenergic agonist.

• DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi
Dupixent (dupilumab) is a monoclonal antibody targeting the alpha chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. Dupilumab is approved in the US to treat patients aged =12 with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. The drug is currently in Phase III of clinical development for COPD.

Chronic Obstructive Pulmonary Disease Emerging Drugs
• Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals
REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role. REGN3500 is being studied in Phase III trial for COPD.

• FASENRA (benralizumab): AstraZeneca
FASENRA (benralizumab), currently in Phase III, is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. Besides, it is an afucosylated IgG which gives it a high affinity for the Fc?RIIIa receptor in natural killer cells, macrophages, and neutrophils.

To learn more about Chronic Obstructive Pulmonary Disease Treatment guidelines, visit @ Chronic Obstructive Pulmonary Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Companies
Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others.

Chronic Obstructive Pulmonary Disease Market Outlook
Chronic Obstructive Pulmonary Disease is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. Abnormalities in the lungs' small airways lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be the destruction of parts of the lung, mucus blocking the airways, inflammation, and swelling of the airway lining. COPD and asthma share common symptoms (coughing, wheezing, and difficulty breathing), and people may have both conditions.

Chronic Obstructive Pulmonary Disease Drugs Market Insights
Many people with COPD have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life. The goal of treating COPD is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. Chronic Obstructive Pulmonary Disease treatment focuses on relieving symptoms, such as coughing and breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of COPD.

Scope of the Chronic Obstructive Pulmonary Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Obstructive Pulmonary Disease Companies- Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others.
• Chronic Obstructive Pulmonary Disease Therapies- Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.
• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease Market Drivers and Barriers
• Chronic Obstructive Pulmonary Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives

Learn more about the FDA-approved drugs for Chronic Obstructive Pulmonary Disease @ Drugs for Chronic Obstructive Pulmonary Disease Treatment- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.